|
|
Click here to invite colleagues
to join the Forum for FREE |
|
|
|
Home | About | PCSK9 | News | Commentary | Trials | Videos | Resources | Contact |
|
Special review Do PCSK9 inhibitors have long-term benefits?
In this specially commissioned review Professor Chris J. Packard discusses the promise of personalized, disease-orientated treatment goals based on the profound LDL-cholesterol lowering effects of PCSK9 inhibitors in people at high risk of premature death from cardiovascular disease.
Legacy effects: A proposed strategy
Professor Chris J. Packard College of Medical, Veterinary and Life Sciences University of Glasgow Scotland
Read Dr Packard’s review »
Forward to colleagues » |
|
|
|
|
For the latest updates, PCSK9 news and analysis. |
|
Hot topics, news and conference reports. |
|
For videos, interviews and webcasts from leading experts. |
|
|
|
|
Educational Partners
and Supporters |
|
|
|
|
|
|
|
|
|
|
|
Copyright PCSK9 Forum 2016.
Please click here to unsubscribe from future mailings. |